IL-28 supplants requirement for Treg cells in protein σ1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE)

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Rynda, Agnieszka ^a,b   Maddaloni, Massimo ^a   Ochoa Repáraz, Javier ^a,b   Callis, Gayle ^a   Pascual, David W ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 28; INTERLEUKIN 4; OVALBUMIN; PROTEIN SIGMA 1; PROTEOLIPID PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS PROTEIN; CAPSID PROTEIN; CYTOKINE; INTERFERON LAMBDA PROTEIN, MOUSE; INTERFERON-LAMBDA PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; SIGMA 1 PROTEIN, REOVIRUS;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; TH2 CELL; ANIMAL; IMMUNOLOGY; PHYSIOLOGY; SERODIAGNOSIS;

MURINAE; ORTHOREOVIRUS;

ANIMALS; ANTIGENS, CD; CAPSID PROTEINS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; NEUTRALIZATION TESTS; T-LYMPHOCYTES, REGULATORY;

EID: 77649244182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008720     Document Type: Article

References (56)

1. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing IL-17. Nat Immunol 6: 133-1141.
2. Wildbaum G, Netzer N, Karin N (2002) Tr1-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Invest 110: 701-710.
3. Faria AMC, Maron R, Ficker SM, Slavin AJ, Spahn T, et al. (2003) Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-β/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun 20: 135-145.
4. + regulatory T cells. J Immunol 172: 5986-5993.
5. Rynda A, Maddaloni M, Mierzejewska D, Ochoa-Repáraz J, Maślanka T, et al. (2008) Low-dose tolerance is mediated by the microfold cells ligand, reovirus protein sigma 1. J Immunol 180: 5187-5200.
6. +T cells. J Immunol 173: 6526-6531.
7. Ochoa-Repáraz J, Riccardi C, Rynda A, Jun S, Callis G, et al. (2007) Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol 178: 1791-1799.
8. Ochoa-Repáraz J, Rynda A, Ascón MA, Yang X, Kochetkova I, et al. (2008) IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol 181: 954-968.
9. + egulatory T cells by TGF-β induction of transcription factor FoxP3. J Exp Med 198: 1875-1886.
10. Pillemer BB, Qi Z, Melgert B, Oriss TB, Ray P, et al. (2009) STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells. J Immunol 183: 155-163.
11. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
12. Mennechet FJ, Uzé G (2006) Interferon lambda treated dendritic cells specifically induce proliferation of FoxP3-expressing suppressor T cells. Blood 107: 4417-4423.
13. Uze G, Monneron D (2007) IL-28 and IL-29: newcomers to the interferon family. Biochimie 89: 729-734.
14. Commins S, Steinke JW, Borish L (2008) The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 121: 1108-1111.
15. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, et al. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113: 5868-5877.
16. Hafler DA (2004) Multiple sclerosis. J Clin Invest 113: 6788-794.
17. Weiner HL (1997) Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 18: 335-343.
18. Gonnella PA, Kodali D, Weiner HL (2003) Induction of low-dose oral tolerance in monocyte chemoattractant protein-1- and CCR2-deficient mice. J Immunol 170: 2316-2322.
19. Miyamoto K, Kingsley CI, Zhang X, Jabs C, Izikson L, et al. (2005) The ICOS molecule plays a crucial role in the development of mucosal tolerance. J Immunol 175: 7341-7347.
20. Faria A, Weiner HL (2006) Oral tolerance: therapeutical implications for autoimmune disease. Clin Dev Immunol 13: 143-157.
21. Masuda K, Horie K, Suzuki R, Yoshikawa T, Hirano K (2002) Oral delivery of antigens in liposomes with some lipid compositions modulates oral tolerance to the antigens. Microbiol Immunol 46: 55-58.
22. Kim WU, Lee WK, Ryoo JW, Kim SH, Kim J, et al. (2002) Suppression of collagen-induced arthritis by single administration of poly (lactic-co-glycolic acid) nanoparticles entrapping type II collagen: A novel treatment strategy for induction of oral tolerance. Arthritis Rheum 46: 1109-1120.
23. Sun JB, Holmgren J, Czerkinsky C (1994) Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 91: 10795-10799.
24. Yuki Y, Byun Y, Fujita M, Izutani W, Suzuki T, et al. (2001) Production of a recombinant hybrid molecule of cholera toxin -B subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol Bioeng 72: 62-69.
25. Fujihashi K, Dohi KT, Rennert PD, Yamamoto M, Koga T, et al. (2001) Peyer's patches are required for oral tolerance to proteins. Proc Natl Acad Sci USA 98: 3310-3315.
26. + T cells. Gastroenterol 153: 917-925.
27. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23 rather than interleukin-12 is the crucial cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
28. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, et al. (2006) Transforming growth factor-β induces development of the T(H)17 lineage. Nature 441: 231-234.
29. Kimura A, Naka T, Kishimoto T (2007) IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 104: 12099-12104.
30. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, et al. (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-b1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98: 70-77.
31. Weiner HL (2004) Current issues in the treatment of human diseases by mucosal tolerance. Ann NY Acad Sci 1029: 211-224.
32. Scadding GK, Brostoff J (1986) Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 16: 483-491.
33. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW (2004) Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 93: 3-12.
34. O'Hehir RE, Sandrini A, Anderson GP, Rolland JM (2007) Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem 14: 2235-2244.
35. Aspord C, Thivolet C (2002) Nasal administration of CTB-insulin induces active tolerization against autoimmune diabetes in non-obese (NOD) mice. Clin Exp Immunol 130: 402-211.
36. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C (1996) Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 93: 7196-7201.
37. Yokohama Y, Harabuchi Y (2002) Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA, and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otohinolaryngol 63: 235-241.
38. Lycke N (2004) ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Ann N Y Acad Sci 1029: 193-208.
39. Bergquist C, Lagergard T, Lindblad M, Holmgren J (1995) Local and systemic antibody response to dextran-cholera toxin B subunit conjugates. Infect Immun 63: 2021-2025.
40. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A (1997) Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 65: 2676-2684.
41. Turner DL, Duncan R, Lee PW (1992) Site-directed mutagenesis of the Cterminal portion of reovirus protein s1: evidence for a conformation-dependent receptor binding domain. Virology 186: 219-227.
42. Faria A, Weiner HL (1999) Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 73: 153-264.
43. Stohlman SA, Pei L, Cua DJ, Li Z, Hinton DR (1999) Activation of regulatory cells suppresses experimental allergic encephalomyelitis via secretion of IL-10. J Immunol 163: 6338-6344.
44. Gonnella PA, Waldner HP, Kodali D, Weiner HL (2004) Induction of low dose oral tolerance in IL-10 deficient mice with experimental autoimmune encephalomyelitis. J Autoimmun 23: 193-200.
45. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, et al. (1996) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718.
46. Selvaraj RK, Geiger TL (2007) A kinetic and dynamic analysis of FoxP3 induced in T cells by TGF-β. J Immunol 178: 7667-7677.
47. + precursors. J Immunol 175: 6107-6116.
48. Kleinschek M, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, et al. (2007) IL-25 regulates IL-17 function in autoimmune inflammation. J Exp Med 204: 161-170.
49. + regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6. J Immunol 180: 7112-7116.
50. Coquet JM, Chakravarti S, Smyth MJ, Godfrey DI (2008) Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol 180: 7097-7101.
51. Herrero C, Hu X, Li WP, Samuels S, Sharif MN, et al. (2003) Reprogramming of IL-10 activity and signaling by IFN-γ. J Immunol 171: 5034-5041.
52. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, et al. (2004) IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172: 6476-6481.
53. Ank N, Paludan SR (2009) Type III IFNs: new layers of complexity in innate antiviral immunity. BioFactors 35: 82-87.
54. Jun S, Gilmore W, Callis G, Rynda A, Haddad A, et al. (2005) A live diarrheal vaccine imprints a Th2 cell bias and acts as an anti-inflammatory vaccine. J Immunol 175: 6733-6740.
55. Kato H, Fujihashi K, Kato R, Yuki Y, McGhee JR (2001) Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses. J Immunol 166: 3114-3121.
56. Min BB, Legge KL, Pack C, Zaghouani H (1998) Neonatal exposure to selfpeptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon γ-mediated splenic anergy. J Exp Med 188: 207-217.